Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

28.08.2018 | short review | Ausgabe 3/2018

memo - Magazine of European Medical Oncology 3/2018

Cure in metastatic disease: how to manage and who is the right patient in GIST

memo - Magazine of European Medical Oncology > Ausgabe 3/2018
MD Ursula Pluschnig


Gastrointestinal stromal tumors (GISTs) are a rare type of cancer and a heterogeneous disease. The tyrosine kinase receptors KIT and the platelet-derived growth factor receptor alpha PDGFRA are the most common mutant genes of GIST. Mutation analysis is a diagnostic standard and is crucial for drug therapy with tyrosine kinase inhibitors (TKI). About 10% of patients already have metastases at first diagnosis. R0 resection is the only curative option in GIST and is therefore the therapy for localized tumors. In case of locally advanced primary tumors, neoadjuvant therapy should be offered. Recurrent, metastatic and locally advanced disease can be treated with TKI; in select cases surgical therapy may be added. The role of surgery in metastatic disease is controversial.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 3/2018

memo - Magazine of European Medical Oncology 3/2018 Zur Ausgabe